LB Pharmaceuticals CMO exits officer role, stays as advisor

LB Pharmaceuticals Inc. announced that Chief Medical Officer Anna Eramo, M.D. resigned her officer role effective June 15, 2026, for personal reasons and will transition to an advisor role.

Rhea-AI Filing Summary

LB Pharmaceuticals Inc. announced that Chief Medical Officer Anna Eramo, M.D. resigned her officer role effective June 15, 2026, for personal reasons and will transition to an advisor role. She will continue providing full-time consulting services through September 15, 2026 while the company searches for a replacement.

The company states that her departure is not related to its clinical program operations or practices and does not expect a material impact on clinical development activities or previously disclosed milestones. Existing clinical development and operations teams will keep overseeing ongoing trials.

Under a Separation and Consulting Agreement dated June 8, 2026, if Dr. Eramo serves through the consulting period and complies with her obligations, she will receive her current base salary paid monthly until June 15, 2027, a prorated 2026 target bonus, and accelerated vesting of 66,143 unvested option shares on September 15, 2026. Her other options continue vesting under existing equity plans, and the company will reimburse COBRA healthcare premiums for up to 12 months, subject to earlier termination conditions.

Insights

Biotech corporate governance analyst

Key medical leader exits officer role but stays on as consultant.

LB Pharmaceuticals is disclosing the planned transition of Chief Medical Officer Anna Eramo, M.D., who resigns her officer role yet continues in a full-time consulting capacity through September 15, 2026. The company explicitly states it does not expect a material impact on ongoing clinical development or milestones.

The Separation and Consulting Agreement grants continued salary to June 15, 2027, a prorated 2026 target bonus, and accelerates vesting of 66,143 option shares on September 15, 2026, while other options keep vesting under existing plans. COBRA reimbursement for up to 12 months adds a standard executive separation benefit.

This looks like a structured leadership transition rather than an abrupt departure. The continuity of her involvement, combined with the company’s experienced clinical teams, suggests operational stability based on the information provided, though future company filings will provide additional detail on the new CMO hire and any evolution of clinical strategy.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

CMO separation date: June 15, 2026 Consulting period end: September 15, 2026 Salary continuation end: June 15, 2027 +2 more

5 metrics

CMO separation date June 15, 2026 Effective date Dr. Eramo resigns as Chief Medical Officer

Consulting period end September 15, 2026 End of full-time consulting period under Separation Agreement

Salary continuation end June 15, 2027 Date through which current base salary is paid monthly

Option acceleration 66,143 shares Unvested option shares vesting on September 15, 2026

COBRA reimbursement period Up to 12 months Maximum duration of post-employment COBRA premium reimbursement

Key Terms

Separation and Consulting Agreement, COBRA, 2023 Stock Incentive Plan, 2025 Equity Incentive Plan, +2 more

6 terms

Separation and Consulting Agreement financial

"In connection with her resignation, Dr. Eramo’s has entered into a separation and consulting agreement"

COBRA financial

"the Company will provide Dr. Eramo with reimbursement of COBRA healthcare premium costs"

COBRA is a U.S. federal law that lets employees and their dependents temporarily keep employer-sponsored health insurance after job loss, reduction in hours, or other qualifying events by paying the premiums themselves. Investors should care because offering COBRA can affect a company’s cash flow, administrative costs and legal disclosures when workforce changes occur—similar to a former club member paying to keep their membership active after leaving the club.

2023 Stock Incentive Plan financial

"will continue to vest in accordance with the Company’s 2023 Stock Incentive Plan"

2025 Equity Incentive Plan financial

"will continue to vest in accordance with the Company’s 2023 Stock Incentive Plan, 2025 Equity Incentive Plan"

forward-looking statements regulatory

"Cautionary Statement Regarding Forward-Looking Statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did LB Pharmaceuticals (LBRX) announce the resignation of its Chief Medical Officer?

LB Pharmaceuticals reported that Chief Medical Officer Anna Eramo, M.D., resigned her officer role effective June 15, 2026, for personal reasons. She will remain engaged as a full-time consultant through September 15, 2026, supporting continuity while the company searches for a permanent replacement.

Will Dr. Eramo’s departure affect LB Pharmaceuticals’ (LBRX) clinical development plans?

The company states Dr. Eramo’s departure is not related to its clinical program operations or practices. LB Pharmaceuticals does not expect a material impact on clinical development activities or previously disclosed clinical milestones and notes that experienced internal teams will continue overseeing ongoing trials.

What compensation will Dr. Anna Eramo receive under her separation from LB Pharmaceuticals (LBRX)?

If Dr. Eramo completes the consulting period and meets her obligations, she will receive her current base salary monthly until June 15, 2027, a prorated 2026 target annual bonus, and accelerated vesting of 66,143 option shares on September 15, 2026, plus continued vesting of other options.

How long will Dr. Eramo continue consulting for LB Pharmaceuticals (LBRX)?

Under the Separation and Consulting Agreement, Dr. Eramo will provide full-time consulting services from the June 15, 2026 separation date through September 15, 2026. During this period, she remains actively involved with the company while no longer serving as Chief Medical Officer.

What healthcare benefits does LB Pharmaceuticals (LBRX) provide to Dr. Eramo after her separation?

LB Pharmaceuticals will reimburse Dr. Eramo’s COBRA healthcare premiums for the same coverage level she had while employed. This reimbursement lasts up to 12 months after the separation date, or ends earlier if COBRA eligibility expires or she gains substantially equivalent coverage elsewhere.

Does LB Pharmaceuticals (LBRX) address risks related to this management change?

The company includes forward-looking statements noting risks such as funding needs, dependence on lead candidate LB-102, regulatory approvals, clinical development timing, competition, and reliance on third parties. It points investors to its Form 10-K and Form 10-Q for more detailed risk factor discussions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 04:16 PM Learn about SEC filing dates

false 0001691082 0001691082 2026-06-08 2026-06-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 8, 2026

LB Pharmaceuticals Inc

(Exact name of registrant as specified in its charter)

Delaware		001-42831		81-1854347
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

One Pennsylvania Plaza, Suite 1025 New York, NY		10119
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 605-0300

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		LBRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

On June 16, 2026, Anna Eramo, M.D., for personal reasons will transition to a role of advisor to LB Pharmaceuticals Inc (the “Company”). On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the “Separation Date”). She will continue to provide consulting services in a full-time capacity to the Company through September 15, 2026. Dr. Eramo’s departure is not related to the Company’s clinical program operations or practices, and the Company does not expect her departure to have a material impact on the Company’s clinical development activities or previously disclosed clinical milestones. A search is underway for her replacement, and the Company has experienced clinical development and operations teams who will continue to oversee the execution of the ongoing clinical trials.

In connection with her resignation, Dr. Eramo’s has entered into a separation and consulting agreement with the Company, dated as of June 8, 2026 (the “Separation Agreement”). Pursuant to the Separation Agreement, Dr. Eramo will provide consulting services to the Company for the three-month period following the Separation Date until September 15, 2026 (the “Consulting Period”). Pursuant to the Separation Agreement, if Dr. Eramo remains engaged as a consultant and complies with her obligations to the Company through the end of the Consulting Period, she will be entitled to (a) her current base salary on a monthly basis until June 15, 2027, (b) 100% of her target annual bonus for 2026 on a prorated basis, and (c) the acceleration of her outstanding stock options such that 66,143 of the unvested shares subject to the her stock options shall be vested and exercisable on September 15, 2026. Throughout the Consulting Period, Dr. Eramo’s existing options will continue to vest in accordance with the Company’s 2023 Stock Incentive Plan, 2025 Equity Incentive Plan and applicable grant agreements. In addition, the Company will provide Dr. Eramo with reimbursement of COBRA healthcare premium costs for the same level of coverage she had during employment until the earlier of (i) 12 months following the Separation Date, (ii) the expiration of Dr. Eramo’s eligibility for the continuation coverage, or (iii) the date Dr. Eramo becomes eligible for substantially equivalent healthcare coverage through another source. The Separation Agreement also contains confidentiality and non-disparagement covenants and a release of claims by Dr. Eramo.

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements include statements with respect to the impact of Dr. Eramo’s departure on the Company’s clinical development activities or previously disclosed clinical milestones, the Company’s ability to successfully find Dr. Eramo’s replacement, and the Company’s continuous execution of the ongoing clinical trials. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including risks and uncertainties related to the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s

business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Report on Form 10-Q for the quarters ended March 31, 2026 and in the Company’s other SEC filings. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1		Separation and Consulting Agreement by and between LB Pharmaceuticals Inc and Anna Eramo, dated June 8, 2026.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LB PHARMACEUTICALS INC
By:		/s/ Heather Turner
		Heather Turner Chief Executive Officer

Dated: June 10, 2026

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

• EX-10.1 EX-10.1 47.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 18.3 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.4 KB